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Coronavirus disease 2019 (COVID-19) remains a major health challenge globally. Previous
studies have suggested that changes in the glycosylation of IgG are closely associated with
the severity of COVID-19. This study aimed to compare the proﬁles of IgG N-glycome
between COVID-19 patients and healthy controls. A case-control study was conducted, in
which 104 COVID-19 patients and 104 age- and sex-matched healthy individuals were
recruited. Serum IgG N-glycome composition was analyzed by hydrophilic interaction
liquid chromatography with the ultra-high-performance liquid chromatography
(HILIC-UPLC) approach. COVID-19 patients have a decreased level of IgG fucosylation,
which upregulates antibody-dependent cell cytotoxicity (ADCC) in acute immune
responses. In severe cases, a low level of IgG sialylation contributes to the ADCCregulated enhancement of inﬂammatory cytokines. The decreases in sialylation and
galactosylation play a role in COVID-19 pathogenesis via the activation of the lectininitiated alternative complement pathway. IgG N-glycosylation underlines the complex
clinical phenotypes of SARS-CoV-2 infection.
Keywords: COVID-19, glycosylation, IgG, SARS-CoV-2, case-control study

INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), remains a global health challenge. COVID-19 has resulted in more than 194.0
million infections and 4.1 million deaths as of July 26, 2021 (1). SARS-CoV-2 is a positive-sense
single-stranded RNA virus with four structural proteins: small envelope (E), matrix (M),
nucleocapsid (N), and spike (S) (2). The transmembrane S protein is extensively glycosylated
with a total of 22 N-linked glycan sequons per protomer which mediate infectivity and immune
escape (3, 4). While understanding that the glycan structures of SARS-CoV-2 potentially assist
vaccines design, antibody therapeutics, screening of small-molecule drugs and their targets (5–7),
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and recognition of the human immunoglobulin G (IgG) glycome
hold the similar relevance to investigate the susceptibility and
complicated clinical phenotypes of the SARS-CoV-2 infection.
As a set of glycoproteins, IgG is attached with two N-linked
glycans at asparagine 297 sites of the fragment crystallizable (Fc)
segments in heavy chains (8, 9). These glycans modulate the
inﬂammatory properties of IgG by changing the afﬁnity for
speciﬁc receptors and lectins (10), which are involved in the
development of inﬂammatory diseases (11–16). Progression of
dengue virus (DENV) infection attributed to antibody-dependent
enhancement (ADE) is proved to be regulated by speciﬁc IgG
glycosylation (17). However, there is limited knowledge on IgG
glycosylation that is associated with SARS-CoV-2 infection.
Recently, the levels of bisecting N-acetylglucosamine (GlcNAc)
and galactosylation of IgG were reported to be negatively
correlated to the severity of the European COVID-19 patients
(18). Meanwhile, IgG afucosylation was observed to be positively
correlated with the severity of COVID-19 (19). Moreover, a study
showed that IgG against SARS-CoV-2 S protein is characterized
by afucosylation, whereas IgG against N protein has a higher level
of fucosylation (20). These ﬁndings support the notion that
changes in IgG glycome composition are closely related to the
loss of the immunosuppressive function and contribute to the
immune-mediated pathologies of SARS-CoV-2 infection (18).
We aimed to proﬁle the IgG N-glycome in COVID-19 patients
by an age- and sex-matched case-control study.

1:7 (v/v). The samples were then transferred to the protein G
monolithic plate, for IgG binding and cleaning, followed by PBS
washing as previously reported. IgG samples were eluted with
1 ml of 0.1 M formic acid and ﬁltered into the collection plate by
a vacuum pump. And, 170 µl of 1 M ammonium bicarbonate was
added to each plate with shock blending.
Isolated IgG samples were denaturized with 20 µl of 2% sodium
dodecyl sulfonate (v/v) in a 65°C oven for 10 min. Then, 10 µl of
4% IGEPAL was added and incubated in a shaking incubator for 5
min. After the samples were regulated by (30 ul) 0.1 mol/L NaOH
and 20 µl of 5 × PBS to a pH of 8.0 with shock blending, then 4 µl
of PNGase F enzyme were added. And the samples were incubated
in a 37°C water bath for N-Glycan release.
The released N-glycans were labeled with 35 µl of 2aminobenzamide(2-AB) mixed solution reagent, and transferred
into an oscillator for about 10 min, then transferred into an oven
at 65°C for 3 h. The 2-AB labeled glycans were puriﬁed by 100%
acetonitrile, and eluted with 100 µl of ultra-pure water. The 2-AB
labeled glycans were transferred into an oven to dry at 60°C for
3.5 h, and then saved at -80°C until further measurement.
N-glycan samples were dissolved with a mixture of 100%
acetonitrile and ultra-pure water at a 2:1 ratio (v/v). Then, it was
centrifuged at 134 g for 5 min and 20 µl of the labeled N-glycans
was loaded into the UPLC instruments. The glycans were
analyzed with hydrophilic interaction liquid chromatography
(HILIC) on a UPLC instrument (Walters Corporation, Milford,
MA) (22, 23). A total of 24 chromatographic glycan peaks (GPs
1–24) were identiﬁed as initial glycans. Each glycan was
quantiﬁed as relative values of the GP to total GPs. The glycan
structure in each peak was matched as previously reported (22).
We further calculated the derived glycans using the measurement
data of the initial GPs, which consist of sialylation trait, bisecting
GlcNAc trait, galactosylation trait, and fucosylation trait (11).
Statistical analyses were performed on each glycan, and also on
the summary features of the IgG glycome composition, i.e., G1:
glycans with one galactose, G2: glycans with two galactoses, G0:
glycans without galactose, S: sialic acid, F: fucose, and B:
bisecting GlcNAc.

MATERIALS AND METHODS
Study Participants
We randomly enrolled 104 COVID-19 patients who were
hospitalized in Chongqing Public Health Medical Center from
January 24 to May 6, 2020. The inclusion criteria are as follows:
(1) diagnosed in accordance with the eighth edition of the
Diagnosis and Treatment Plan for COVID-19 issued by the
National Health Commission of China both male and female
patients with COVID-19; (2) deﬁnitive diagnosis using
polymerase chain reaction (PCR) test; (3) did not receive
vaccines in the preceding 6 months; and (4) not enrolled in
other clinical trials. The exclusion criteria are as follows:
(1) patients with other viral diseases; (2) patients who have been
undergoing chemotherapy for the past month; (3) patients with
severe diseases, such as coronary heart disease, stroke, and cancers;
and (4) patients with autoimmune diseases. All patients were
recruited at the ﬁrst week of hospitalization. As controls, 104 ageand sex-matched healthy participants were enrolled from a local
community-based cohort. The Ethical Committee of Chongqing
General Hospital approved this study (No. S2020-021-01).
Informed consent was obtained from each study participant.

Statistical Analysis
Normal distribution of all analysis results was checked using the
Kolmogorov-Smirnov test. Continuous variables underlying the
abnormal distribution were represented as the medians
(interquartile ranges). The difference of continuous variables
between two groups was tested using the Wilcoxon rank-sum
test. Statistical analyses were carried out with the SPSS software,
version 25.0 (IBM, New York, USA). All reported P-values were
two-sided, and a P < 0.05 was considered statistically signiﬁcant.

RESULTS

Analysis of Immunoglobulin G Glycans

Characteristics of Study Participants

Isolation of IgG and release of N-glycans were performed as
described previously (21, 22). Brieﬂy, the frozen sera were
thawed, and were centrifugated at 80 g for 10 min. Dilute the
samples with 1× phosphate-buffered saline (PBS, pH = 7.4) by

Frontiers in Immunology | www.frontiersin.org

In this case-control study, we recruited 104 COVID-19 patients (50
men/54 women, mean age 44.81 years) from Chongqing Public
Health Medical Center, Chongqing, China. Simultaneously, 104

2

September 2021 | Volume 12 | Article 748566

Hou et al.

IgG Proﬁle of COVID-19 Patients

and GP23) were signiﬁcantly higher in COVID-19 patients than
that of the controls (Table S2), whereas another 12 GPs (GP2,
GP4, GP6, GP8, GP9, GP10, GP12, GP14, GP16, GP18, GP19,
and GP24) were lower in COVID-19 patients. We further
calculated the derived glycans traits using the measurement
data of the initial GPs, which consist of sialylation, bisecting
GlcNAc, galactosylation trait, and fucosylation traits (11). As
listed in Table S2, 39 of 54 derived glycans were differential
between the COVID-19 patients and the controls.

age- and sex-matched healthy participants were enrolled from a
local community-based cohort. Of the 104 COVID-19 patients, 18
were severe cases (with respiratory rate ≥ 30 times/min, oxygen
saturation ≤ 93% on ambient air), and 86 were mild cases. The
characteristics of the study participants are shown in Table 1.

The Immunoglobulin G Glycome
Composition in Participants
A total of 24 initial glycan peaks (GP1–GP24) were obtained
from all the chromatograms of UPLC. As shown in Table S1, 10
GPs (GP1, GP3, GP5, GP11, GP13, GP17, GP20, GP21, GP22,

Fucosylation
Afucosylation upregulates the capability of IgG to trigger
antibody-dependent cell cytotoxicity (ADCC) and leads to the
enhancement of inﬂammatory cytokines produced by monocytes.
An increase in IgG afucosylation has been observed among severe
COVID-19 patients in earlier studies involving Caucasian
populations (18, 20). As shown in Figure 1, 14 fucosylated
glycans (GP4, GP6, GP8, GP9, GP10, GP14, GP16, GP18, GP19,
Fn total, FG2n total/G2n, Fn, FG1n/G1n, and FG2n/G2n) were
signiﬁcantly lower in the COVID-19 group when compared to
the controls. The percentage of glycans with fucose was 82.54% in
the COVID-19 cases, which was signiﬁcantly lower than that in
the control group (95.64%) (Table 2).
However, the levels of fucosylated IgG in the severe COVID19 cases (87.94%) were signiﬁcantly higher than those in the mild
cases (85.54%), which might be attributed to the heterogeneity of
age between severe and mild cases (Table 3). Furthermore, we
analyzed the core fucosylation of IgG in the severe COVID-19
cases compared to the mild patients. As listed in Table S3, no
differences in core fucosylated moieties were identiﬁed between
the severe and mild cases.

TABLE 1 | Characteristics of study participants.
Variables

Sex (men/women)
Age
WBC
RBC
PLT
ALT
AST
Cr
UA
FBG
Hypertension
Hyperlipidemia
Hyperuricemia
Diabetes

COVID-19 patients
(n = 104)

Controls
(n = 104)

P

50/54
44.81 ± 13.96
5.31 (4.23–6.73)
4.35 (3.95–4.65)
201.00 (266.00–272.00)
22.00 (17.00–39.00)
20.00 (17.00–27.00)
64.55 (57.60–74.18)
307.77 ± 86.06
5.72 (5.32–7.06)
6 (5.77%)
2 (1.92%)
1 (0.96%)
11 (10.58%)

50/54
44.62 ± 11.629
6.02 (4.89–7.11)
4.67 (4.25–5.04)
262.00 (222.00–296.00)
24.00 (18.00–33.00)
21.00 (18.00–26.00)
66.00 (57.00–74.00)
305.22 ± 74.82
5.67 (5.32–6.21)
0
0
0
0

–
0.918
0.005
<0.001
<0.001
0.357
0.518
0.921
0.588
0.118
–
–
–
–

ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine;
FBG, fasting blood glucose; PLT, platelet; RBC, red blood cell; UA, serum uric acid; WBC,
white blood cell.

FIGURE 1 | Fucosylation on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan
peak; S, Sialic acid; ↑, the glycan in COVID-19 group is signiﬁcantly higher than that in the controls; ↓, the glycan in COVID-19 group is signiﬁcantly lower than that in
the controls.
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TABLE 2 | Relative abundance (%) of the main IgG glycome features in COVID-19 patients and the healthy controls.
Summary glycans
Fucosylation
Bisecting GlcNAc
Galactosylation
Sialylation

COVID-19 patients (n = 104)

Controls (n = 104)

Z

P

82.54 (72.36–87.21)
14.30 (12.57–15.66)
76.13 (67.14–83.02)
29.68 (21.75–39.29)

95.64 (94.12–96.69)
15.39 (13.48–17.08)
69.21 (63.41–72.93)
20.60 (17.48–23.82)

10.874
2.398
4.668
6.296

<0.001
0.016
<0.001
<0.001

GlcNAc, N-acetylglucosamine.

level of total sialylated glycans was observed in the severe patients
(18.93%) than that in the mild cases (26.09%) (Table 3).

Sialylation
IgG sialylation, also known as N-acetylneuraminic acid (Neu5Ac)linked IgG, regulates pro-inﬂammation and anti-inﬂammation
balance. The decrease in IgG sialylation upregulates the antibodydependent cell cytotoxicity (ADCC) pathway and is linked to
activation of the lectin-initiated alternative complement pathway
(24). In this study, 11 sialylated glycans (GP17, GP21, GP22, GP23,
FGS/(FG+FGS), FGS/(F+FG+FGS), FG2S1/(FG2+FG2S1+FG2S2),
FG2S2/(FG2+FG2S1+FG2S2), FBG2S1/(FBG2+FBG2S1+
FBG2S2), FtotalS1/FtotalS2, and FBS1/FBS2) were higher in the
COVID-19 patients (Figure 2). In total, a higher abundance of
sialylated glycans was identiﬁed in the COVID-19 group (29.68%)
than that in the controls (20.60%) (Table 2). Meanwhile, a lower

Bisecting GlcNAc
With regard to bisecting GlcNAc, the decrease of GP6, GP10,
GP19, GP24, FBStotal/FStotal, FBS2/FS2, and FBS2/(FS2+FBS2)
were identiﬁed in the COVID-19 cases (Figure 3). The
percentage of glycans with bisecting GlcNAc was signiﬁcantly
lower in the COVID-19 cases (14.30%) than that in the controls
(15.39%) (Table 2). Nevertheless, no difference in the total
bisecting N-GlcNAc was found between the severe and mild
cases (13.22% vs. 15.38%) (Table 3).

TABLE 3 | Relative abundance (%) of the main IgG glycome features in severe and mild COVID-19 patients.
Summary glycans
Fucosylation
Bisecting GlcNAc
Galactosylation
Sialylation

Severe patients (n = 18)

Mild patients (n = 86)

87.94 (82.05–92.63)
13.22 (11.81–15.68)
58.32 (53.57–62.47)
18.93 (8.73–24.81)

85.54
15.38
74.07
26.09

(82.22–90.22)
(13.48–17.08)
(64.54–75.71)
(17.79–32.33)

Z

P

3.342
1.413
4.734
3.746

0.001
0.158
<0.001
<0.001

GlcNAc, N-acetylglucosamine.

FIGURE 2 | Sialylation on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan peak;
S, Sialic acid; ↑, the glycan in COVID-19 group is signiﬁcantly higher than that in the controls; ↓, the glycan in COVID-19 group is signiﬁcantly lower than that in the controls.
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FIGURE 3 | Bisecting GlcNAc on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan peak; S,
Sialic acid; ↑, the glycan in COVID-19 group is signiﬁcantly higher than that in the controls; ↓, the glycan in COVID-19 group is signiﬁcantly lower than that in the controls.

divided into three tertile groups. As shown in Table S5, there
were no signiﬁcant differences between the three groups.
Meanwhile, no differences were observed between men and
women (Table S6).

Galactosylation
Agalactosylated IgG is recognized to be associated with the activation
of the lectin-initiated complement pathway in the development of
inﬂammatory diseases (11). As shown in Figure 4, the level of
galactosylated glycans was signiﬁcantly higher in the COVID-19
patients (76.13%) when compared to the controls (69.21%) (Table 2).
Furthermore, a decrease in galactosylated IgG was identiﬁed in the
severe COVID-19 cases (58.32%) than that in the mild cases
(74.07%) (Table 3), meaning that agalactosylated IgG plays a role
in the inﬂammatory process among severe COVID-19 cases.

DISCUSSION
Our ﬁndings reafﬁrm that SARS-CoV-2 infection is associated with
the absence of the fucosylation of IgG, which triggers ADCCregulated acute immune responses. Compared to the mild cases, the
severe ones might have a lower level of IgG sialylation, which leads
to the ADCC-regulated enhancement of inﬂammatory cytokines
and activation of the lectin-initiated alternative complement
pathway. In severe cases, the decreases in sialylation and
galactosylation might also play a role in the activation of the
lectin-initiated alternative complement pathway (Figure 5).
Cytokine storm resulting from the overactivation of the
innate immune system is one of the key features of severe
COVID-19 but signiﬁcantly varies between individuals (25).
Besides, increased levels of pro-inﬂammatory cytokines are not
observed in all severe patients (26). Inter-patient differences in
the IgG glycome proﬁles are apparent and reﬂect both genetic
and environmental determinants (27), which hypothetically
contribute to the abnormal expression of glycosyltransferase
and glycosidase in plasma cells or B cells, resulting in the
different susceptibility of the SARS-CoV-2 infection and
severity of the COVID-19. These changes in the IgG glycome

Time Trend of Immunoglobulin G
Glycosylation Proﬁles
A previous follow-up study demonstrated that the IgG level increases
from the ﬁrst week of symptom onset to the ﬁfth week, then maintains
a stable level until the seventh week. In order to explore if the IgG
glycosylation proﬁle follows a certain trajectory, we followed-up 23
patients for 4 weeks, and recorded the IgG N-glycans in the ﬁrst week,
two to three weeks, and the fourth week after their clinical diagnoses.
As shown in Table S4, the levels of the 24 initial glycans detected by
HILIC-UPLC were not signiﬁcantly different between the three
follow-up durations, indicating that the IgG glycosylation proﬁle is
relatively stable after the clinical symptom onset.

Age- and Sex-Differences in
Immunoglobulin G Glycosylation
The relative proportions (%) of the main IgG glycome features
were compared between the COVID-19 patients who were
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FIGURE 4 | Galactosylation on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan
peak; S, Sialic acid; ↑, the glycan in COVID-19 group is signiﬁcantly higher than that in the controls; ↓, the glycan in COVID-19 group is signiﬁcantly lower than that in
the controls.

monocytes, including interleukin-1b (IL-1b), IL-6, tumor
necrosis factor-a (TNF-a), C-reactive protein (CRP), and
Interferon-g (IFN-g) (19, 31). This might be the pathway that
IgG afucosylation modulates cytokine storm during the active
phase of the SARS-CoV-2 infection.
IgG sialylation-regulated ADCC plays a role in the proinﬂammation and anti-inﬂammation balance in the pathway
similar to fucosylation (32). The absence of sialylation IgG
reduces its efﬁcacy to complement-dependent cytotoxicity
(CDC) activity via C1q binding and leads to an increase in the
activation of the lectin-initiated alternative complement pathway
(24). In this current study, a higher abundance of sialylated
glycans was identiﬁed in the COVID-19 group than that in the
controls, reﬂecting the general features in acute immune
responses (20). Higher levels of bisecting GlcNAc on IgG
enhance ADCC via increased FcgRIII binding and elevate the
proinﬂammatory function of IgG (33). We found that the total
glycans with bisecting GlcNAc was signiﬁcantly lower in the
COVID-19 cases than that in the controls. This might cause a
decrease in the modulation of the inﬂammatory response among
COVID-19 patients, but to a lower degree than that of
fucosylation (11). Agalactosylated IgG is associated with the
activation of the lectin-initiated complement pathway in the
development of inﬂammatory diseases (34). However, we found
that the levels of agalactosylated glycans were decreased in the
COVID-19 patients.

may make it possible to switch between anti-inﬂammatory and
pro-inﬂammatory effects upon antigenic challenge (28).
Increased cytokines and chemokines activated peripheral
immune cells such as neutrophils and monocytes, penetrate
lung tissue, and cause impairments on target cells (29).
Consequently, IgG glycosylation might play a cascading role in
the progression of COVID-19 pathogenesis.
Here, a signiﬁcant decrease in the fucosylation of IgG was
identiﬁed in the COVID-19 cases compared to the healthy
controls. This ﬁnding is partly consistent with an earlier study
(20), in which a decrease in fucosylated IgG against S protein and
an increase in fucosylated IgG against N protein were observed
among severe COVID-19 patients compared to the mild ones.
However, the underlying mechanism that induces these
differences was not elucidated. In our study, the total IgGs
against multiple antigenic epitopes were examined, including
both anti-S and anti-N IgGs. An earlier study showed that
COVID-19 patients have substantially higher anti-glycan
antibodies (i.e., IgG and IgM) against self-glycans (e.g., Nglycans, LacNAc-containing glycans, gangliosides, sialyl Lewis
X, and blood group H), compared to healthy controls (30).
Nevertheless, it is understood that the absence of fucose
increases the capability of IgG to trigger antibody-dependent
cell cytotoxicity (ADCC) via binding to IgG-speciﬁc Fc gamma
receptor IIIa (FcgRIIIa) on natural killer (NK) cells, resulting in
the enhancement of inﬂammatory cytokines produced by
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FIGURE 5 | The hypothesized roles of IgG N-glycosylation in the immunopathology of COVID-19. In COVID-19 cases, afucosylation of IgG Fc segment activates the
antibody-dependent cell mediated cytotoxicity (ADCC) by ligating to FcgRIIIa on natural killer (NK) cells, macrophage, and neutrophil, and then upregulates the
release of proinﬂammatory factors (e.g., IL-1b, IL-6, CRP, TNF-a, and IFN-g). Among severe cases, agalactosylation and asialylation of IgG upregulates the activation
of the lectin-initiated complement pathway, underlying the complex clinical phenotypes during SARS-CoV-2 infection.

the early stage of infection. Thereby, studies exploring biomarkers
that predict disease association are commonly cross-sectional
studies, which would not allow us to distinguish whether the
reported determinants are pre-existing risk factors (18). Our
follow-up study on the IgG glycosylation proﬁles proved that
the IgG glycome proﬁles are stable from the ﬁrst week of symptom
onset to the fourth week. This makes it predominantly believed
that associations between the IgG glycome composition and
SARS-CoV-2 infection reﬂect a pre-existing predisposition. Our
ﬁnding, in another aspect, validated the previous inference that no
correlation exists between any IgG glycosylations and viral RNA
load during SARS-CoV-2 virus infection (19).
Despite SARS-CoV-2, two coronavirus-induced epidemics have
appeared over the past two decades, including SARS-CoV in 2003
and MERS-CoV in 2012. Researchers have observed an increase in
ADCC activity induced by afucosylated anti-MERS antibodies than
their fucosylated counterparts, which provides a novel perspective
for evaluating the role of the modiﬁcation of N-glycosylation of the
Fc segment in improving ADCC activity (37). Moreover,
mechanistic experiments demonstrated that during dengue
infection, afucosylated IgG promotes FcgRIIIa signaling, and then
enhances replication of the virus in monocytes (38). In addition,
dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS)
patients respond to infection by producing IgGs with enhanced
afﬁnity for the activating FcgRIIIa due to Fc afucosylation (17).

The anti-inﬂammatory and pro-inﬂammatory balance related
to pulmonary immunopathology after SARS-CoV-2 infection
might provide a possible explanation for COVID-19 patients
with mild vs. severe clinical phenotypes. Hereby, we compared
the differences of glycan traits between the severe and mild
COVID-19 patients to explore the roles of IgG glycosylation in
the development of SARS-CoV-2 infection between individuals.
Lower levels of sialylated IgG glycans and galactosylated glycans
were observed in the severe patients compared to the mild ones.
These results support earlier ﬁndings in the European COVID19 patients (18), suggesting that the lectin-initiated alternative
complement pathway modulated by the decreased sialylation
and galactosylation might induce a severe inﬂammatory process
in severe COVID-19 (11). It was noted that the mild cases (mean
age 42.3 years) are signiﬁcantly younger than the severe cases
(mean age 57.0 years). Since aging is one of the main factors
inducing the decrease of IgG sialylation and galactosylation (35,
36), the lower levels of sialylation and galactosylation in severe
cases might be partly attributed to a higher age.
Only a small number of patients infected with SARS-CoV-2
develop severe COVID-19, suggesting that there are some
predisposing factors. Although the pre-existing components of
the total IgG pool before SARS-CoV-2 infection are not consistent
with that following the infection, it is hypothesized that the
glycome proﬁle of IgG might be of little variation, especially in
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Nearly 45% of individuals infected by SARS-CoV-2 present
asymptomatic (39), but there was little opportunity to enroll such
participants in our study. No asymptomatic cases were enrolled in
our study, which limited the representability of our results. In
addition, anti-viral agents and comorbidities might impact the IgG
glycome proﬁles. Despite these limitations, we proﬁled the IgG
glycome in Chinese COVID-19 patients, which contributes to
understanding the immune response to the SARS-CoV-2 infection.
In conclusion, compared to the age- and sex-matched healthy
controls, COVID-19 patients have a decrease in fucosylated IgG,
which upregulates ADCC in acute immune responses. In severe
cases, a low level of IgG sialylation contributes to the
ADCC-regulated enhancement of inﬂammatory cytokines. The
decreases in sialylation and galactosylation that activate the
lectin-initiated alternative complement pathway also play a
role in COVID-19 pathogenesis, which underlines the complex
clinical phenotypes of the SARS-CoV-2 infection.
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11. Russell AC, Š imurina M, Garcia MT, Novokmet M, Wang Y, Rudan I, et al. The
N-Glycosylation of Immunoglobulin G as a Novel Biomarker of Parkinson’s
Disease. Glycobiology (2017) 27(5):501–10. doi: 10.1093/glycob/cwx022
12. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, et al.
Anti-HA Glycoforms Drive B Cell Afﬁnity Selection and Determine Inﬂuenza
Vaccine Efﬁcacy. Cell (2015) 162(1):160–9. doi: 10.1016/j.cell.2015.06.026
13. Biermann MH, Griffante G, Podolska MJ, Boeltz S, Stürmer J, Muñoz LE, et al. Sweet
But Dangerous - the Role of Immunoglobulin G Glycosylation in Autoimmunity
and Inﬂammation. Lupus (2016) 25(8):934–42. doi: 10.1177/0961203316640368
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